Close Menu

NEW YORK – Jiangsu Alphamab Biopharmaceuticals announced today that it has obtained access to palbociclib (Ibrance) through a supply agreement with Pfizer and that this will enable it to conduct a study combining its investigational KNO26 and palbociclib in HER2-positive breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.